Skip to main content
OpenTrials

Clinical trial condition

Haemophilus Influenzae Type b

Explore clinical trials studying Haemophilus Influenzae Type b. Study availability and eligibility vary by location and protocol.

83 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Haemophilus Influenzae Type b trial results

Completed

Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants

NCT00871338

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Ely, Cambridgeshire, United Kingdom
  • GSK Investigational Site Southampton, Hampshire, United Kingdom
  • GSK Investigational Site Oxford, Oxfordshire, United Kingdom
  • GSK Investigational Site Bristol, United Kingdom
View Trial Details
Completed

Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines

NCT00891176

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Bad Saulgau, Baden-Wurttemberg, Germany
  • GSK Investigational Site Bretten, Baden-Wurttemberg, Germany
  • GSK Investigational Site Ettenheim, Baden-Wurttemberg, Germany
  • GSK Investigational Site Karlsruhe, Baden-Wurttemberg, Germany
View all 28 locations
View Trial Details
Completed

Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB

NCT00359983

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Little Rock, Arkansas, United States
  • GSK Investigational Site Fountain Valley, California, United States
  • GSK Investigational Site Norwich, Connecticut, United States
  • GSK Investigational Site Marietta, Georgia, United States
View all 21 locations
View Trial Details
Completed

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

NCT00345579

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Benton, Arkansas, United States
  • GSK Investigational Site Fayetteville, Arkansas, United States
View all 63 locations
View Trial Details
Completed

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

NCT00345683

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Benton, Arkansas, United States
  • GSK Investigational Site Jonesboro, Arkansas, United States
View all 57 locations
View Trial Details
Completed

Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine

NCT00327184

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Espoo, Finland
  • GSK Investigational Site Helsinki, Finland
  • GSK Investigational Site Helsinki, Finland
  • GSK Investigational Site Jarvenpaa, Finland
View all 16 locations
View Trial Details

Related conditions